Recombinant allergens for diagnosis of type I allergy;Rekombinante allergene für die diagnose der typ I-allergie

LaboratoriumsMedizin

Volumn 29, Issue 4, 2005, Pages 263-271

  Mothes, Nadine ^a   Valenta, Rudolf ^a   Spitzauer, Susanne ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Component resolved diagnosis (CRD); Crosssensitization; Hypoallergenic derivatives; Microarrayed allergens; Recombinant allergens; Specific immunotherapy; Type I allergy

Indexed keywords

ALLERGEN; EPITOPE; IMMUNOGLOBULIN G ANTIBODY; VACCINE;

ALLERGY TEST; ANTIBODY SPECIFICITY; ANTIGEN DETECTION; ASTHMA; CLINICAL PRACTICE; CLINICAL TRIAL; DIAGNOSTIC TEST; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNOTHERAPY; IN VITRO STUDY; MEASUREMENT; MOLECULAR BIOLOGY; MOLECULE; MONITORING; PATIENT; PATIENT SELECTION; REVIEW; RHINOCONJUNCTIVITIS; SYMPTOM;

EID: 24044535484     PISSN: 03423026     EISSN: None     Source Type: Journal    
DOI: 10.1515/JLM.2005.037     Document Type: Review

References (83)

1. Casolaro S, Georas SN, Song Z, Ono SJ. Biology and genetics of atopic disease. Curr Opin Immunol 1996;8:796-803.
2. Kay AB. Allergy and Allergic Diseases. Oxford: Blackwell Science1997.
3. Wills-Karp M, Santeliz J, Karp CL. The germless theory of allergic disease: revisiting the hygiene hypothesis. Nat Rev Immunol 2001;1:69-75.
4. Segal DM, Taurog JD, Metzger H. Dimeric immunoglobulin E serves as a unit signal for mast cell degranulation. Proc Natl Acad Sci USA 1977;74:2993-7.
5. van der Veen MJ, Mulder M, Witteman AM, van Ree R, Aalberse RC, Jansen HM, et al. False-positive skin prick test responses to commercially available dog dander extracts caused by contamination with house dust mite (Dermatophagoides pteronyssinus) allergens. J Allergy Clin Immunol 1996;98:1028-32.
6. Valenta R, Kraft D. Recombinant allergens for diagnosis and therapy of allergic diseases. Curr Opin Immunol 1995;7:751-6.
7. Valenta R, Duchene M, Vrtala S, Birkner T, Ebner C, Hirschwehr R, et al. Recombinant allergens for immunoblot diagnosis of tree-pollen allergy. J Allergy Clin Immunol 1991;88:889-94.
8. Valenta R, Vrtala S, Ebner C, Kraft D, Scheiner O. Diagnosis of grass pollen allergy with recombinant timothy grass (Phleum pratense) pollen allergens. Int Arch Allergy Immunol 1992;97:287-94.
9. Ebner C, Szepfalusi Z, Ferreira F, Jilek A, Valenta R, Parronchi P, et al. Identification of multiple T cell epitopes on Bet v 1; the major birch pollen allergen, using specific T cell clones and overlapping peptides. J Immunol 1993;150:1047-54.
10. Valenta R, Sperr WR, Ferreira F, Valent P, Sillaber C, Tejkl M, et al. Induction of specific histamine release from basophils with purified natural and recombinant birch pollen allergens. J Allergy Clin Immunol 1993;91:88-97.
11. Sehon AH, Mohapatra SS. Induction of IgE antibodies in mice with recombinant grass pollen allergens. J Allergy Clin Immunol 1993;91:88-97.
12. Ferreira F, Mayer P, Sperr WR, Valent P, Seiberler S, Ebner C, et al. Induction of IgE antibodies with predefined specificity in rhesus monkeys with recombinant birch pollen allergens, Bet v 1 and Bet v 2. J Allergy Clin Immunol 1996;97:95-103.
13. Vrtala S, Mayer P, Ferreira F, Susani M, Sehon AH, Kraft D, et al. Induction of IgE antibodies in mice and rhesus monkeys with recombinant birch pollen allergens; different allergenicity of Bet v 1 and Bet v 2. J Allergy Clin Immunol 1996;98:913-21.
14. Moser M, Crameri R, Brust E, Suter M, Mentz G. Diagnostic value of recombinant Aspergillus fumigatus allergen I/a for skin testing and serology. J Allergy Clin Immunol 1994;93:1-11.
15. 2 from honeybee venom is similar. J Allergy Clin Immunol 1995;96:395-402.
16. Menz G, Dolecek C, Schönheit-Kenn U, Ferreira F, Moser M, Schneider T, et al. Serological and skin-test diagnosis of birch pollen allergy with recombinant Bet v 1, the major birch pollen allergen. Clin Exp Allergy 1996;26:50-60.
17. Pauli G, Oster JP, Deviller P, Heiss S, Bessot JC, Susani M, et al. Skin testing with recombinant allergens rBet v 1 and birch profilin, rBet v 2: diagnostic value for birch pollen and associated allergies. J Allergy Clin Immunol 1996;97:1100-9.
18. Lynch NR, Thomas WR, Chua Y, Garcia N, Diprisco MC, Lopez R. In vivo biological activity of recombinant Der p 2 allergen of house-dust mite. Int Arch Allergy Immunol 1994;105:70-4.
19. Sidoli A, Tamborini E, Giuntini I, Levi S, Volonte G, Paini C, et al. Cloning, expression and immunological characterization of recombinant Lolium perenne allergen Lol p II. J Biol Chem 1993;268:21819-25.
20. Valenta R, Lidholm J, Niederberger V, Hayek B, Kraft D, Grönlund H. The recombinant allergen-based concept of component-resolved diagnostics and immunotherapy (CRD and CRIT). Clin Exp Allergy 1999;29:896-904.
21. Hiller R, Laffer S, Harwanegg C, Huber M, Schmidt WM, Twardosz A, et al. Microarrayed allergen molecules: diagnostic gatekeepers for allergy treatment. FASEB J 2002;16:414-6.
22. Harwanegg C, Laffer S, Hiller R, Mueller MW, Kraft D, Spitzauer S, et al. Microarrayed recombinant allergens for diagnosis of allergy. Clin Exp Allergy 2003;33:7-13.
23. Suck R, Nandy A, Weber B, Stock M, Fiebig H, Cromwell O. Rapid method for arrayed investigation of IgE-reactivity profiles using natural and recombinant allergens. Allergy 2002;57:821-4.
24. Deinhofer K, Sevcik H, Balic N, Harwanegg C, Hiller R, Rumpold H, et al. Microarrayed allergens for IgE profiling. Methods 2004;32:249-54.
25. Ball T, Sperr WR, Valent P, Lidholm J, Spitzauer S, Ebner C, et al. Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy. Eur J Immunol 1999;29:2026-36.
26. Mothes N, Heinzkill M, Drachenberg KJ, Sperr WR, Krauth MT, Majlesi Y, et al. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy 2003;33:1198-208.
27. van Neerven RJ, Wikborg T, Lund G, Jacobsen B, Brinch-Nielsen A, Arnved J, et al. Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation. J Immunol 1999;163:2944-52.
28. Flicker S, Valenta R. Renaissance of the blocking antibody concept in type I allergy. Int Arch Allergy Immunol 2003;132:13-24.
29. Nouri-Aria KT, Wachholz PA, Francis JN, Jacobson MR, Walker SM, Wilcock LK, et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 2004;172:3252-9.
30. Wachholz PA, Soni NK, Till SJ, Durham SR. Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J Allergy Clin Immunol 2003;112:915-22.
31. Wachholz PA, Durham SR. Mechanisms of immunotherapy: IgG revisited. Curr Opin Allergy Clin Immunol 2004;4:313-8.
32. Niederberger V, Horak F, Vrtala S, Spitzauer S, Krauth MT, Valent P, et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci USA 2004;101:14677-82.
33. Reisinger J, Horak F, Pauli G, van Hage-Hamsten M, Cromwell O, König F, et al. Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity. J Allergy Clin Immunol 2005, in press.
34. Marsh DG, Goodfriend L, King TP, Lowenstein H, Platts-Mills TA. Allergen nomenclature. Bull World Health Organ 1986;64:767-74.
35. Pauli G. Evolution in the understanding of cross-reactivities of respiratory allergens: the role of recombinant allergens. Int Arch Allergy Immunol 2000;123:183-95.
36. Valenta R, Duchene M, Ebner C, Valent P, Sillaber C, Deviller P, et al. Profilins constitute a novel familiy of functional plant pan-allergens. J Exp Med 1992;175:377-85.
37. Vallier P, DeChamp C, Valenta R, Vial O, Deviller P. Purification and characterization of an allergen from celery immunochemically related to an allergen present in several other plant species. Identification as a profilin. Clin Exp Allergy 1992;22:774-82.
38. van Ree R, Voitenko V, van Leeuwen WA, Aalberse RC. Profilin is a cross-reactive allergen in pollen and vegetable foods. Int Arch Allergy Immunol 1992;98:97-104.
39. Moverare R, Westritschnig K, Svensson M, Hayek B, Bende M, Pauli G, et al. Different IgE reactivity profiles in birch pollen-sensitive patients from six European populations revealed by recombinant allergens: an imprint of local sensitization. Int Arch Allergy Immunol 2002;128:325-35.
40. Moverare R, Elfman L, Vesterinen E, Metso T, Haahtela T. Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and the Pharmacia CAP System. Allergy 2002;57:423-30.
41. van Ree R, Antonicelli L, Akkerdaas JH, Garritani MS, Aalberse RC, Bonifazi F. Possible induction of food allergy during mite immunotherapy. Allergy 1996;51:108-13.
42. Twardosz A, Hayek B, Seiberler S, Vangelista L, Elfman L, Gronlund H, et al. Molecular characterization, expression in Escherichia coli, and epitope analysis of a two EF-hand calcium-binding birch pollen allergen, Bet v 4. Biochem Biophys Res Commun 1997;239:197-204.
43. Valenta R, Hayek B, Seiberler S, Bugajska-Schretter A, Niederberger V, Twardosz A, et al. Calcium-binding allergens: from plants to man. Int Arch Allergy Immunol 1998;117:160-6.
44. Tinghino R, Twardosz A, Barletta B, Eleonora MR, Puggioni BD, Iacovacci P, et al. Molecular, structural, and immunologic relationships between different families of recombinant calcium-binding pollen allergens. J Allergy Clin Immunol 2002;109:314-20.
45. Verdino P, Westritschnig K, Valenta R, Keller W. The crossreactive calcium-binding pollen allergen, Phl p 7, reveals a novel dimer assembly. EMBO J 2002;21:5007-16.
46. Verdino P, Westritschnig K, Valenta R, Keller W. Three-dimensional structure of the panallergen Phl p 7. Int Arch Allergy Immunol 2003;130:10-1.
47. Andersson K, Lidholm J. Characteristics and immunobiology of grass pollen allergens. Int Arch Allergy Immunol 2003;130:87-107.
48. Niederberger V, Laffer S, Fröschl R, Kraft D, Rumpold H, Kapiotis M, et al. IgE antibodies to recombinant pollen allergens (Phl p 1, Phl p 2, Phl p 5, and Bet v 2) account for a high percentage of grass pollen-specific IgE. J Allergy Clin Immunol 1998;101:258-64.
49. Vrtala S, Fischer S, Grote M, Vangelista L, Pastore A, Sperr WR, et al. Molecular, immunological, and structural characterization of Phl p 6, a major allergen and P-particleassociated protein from timothy grass (Phleum pratense) pollen. J Immunol 1999;163:5489-96.
50. Laffer S, Valenta R, Vrtala S, Susani M, van Ree R, Kraft D, et al. Complementary DNA cloning of the major allergen Phl p 1 fromtimothy grass (Phleum pratense); recombinant Phl p 1 inhibits IgE binding to group I allergens from eight different grass species. J Allergy Clin Immunol 1994;94:689-98.
51. Kazemi-Shirazi L, Niederberger V, Linhart B, Lidholm J, Kraft D, Valenta R. Recombinant marker allergens: diagnostic gatekeepers for the treatment of allergy. Int Arch Allergy Immunol 2002;127:259-68.
52. Pittner G, Vrtala S, Thomas WR, Weghofer M, Kundi M, Horak F, et al. Component-resolved diagnosis of housedust mite allergy with purified natural and recombinant mite allergens. Clin Exp Allergy 2004;34:597-603.
53. Gronlund, H, Bergman T, Sandstrom K, Alvelius G, Reininger R, Verdino P, et al. Formation of disulfide bonds and homodimers of the major cat allergen Fel d 1 equivalent to the natural allergen by expression in Escherichia coli. J Biol Chem 2003;278:40144-51.
54. Valenta R. Diagnostic tests based on recombinant allergens: Assistants for the selection of allergy therapies. In Wall K, editor: New Horizons - Allergy, Vol 1. Uppsala (Sweden): Pharmacia Diagnostics AB, 2002:1-6.
55. Westritschnig K, Kraft D, Valenta R. Rekombinante Allergene in der Diagnose der Typ I Allergie. J Lab Med 2002;26:120-9.
56. Valenta R, Ball T, Focke M, Linhart B, Mothes N, Niederberger V, et al. Immunotherapy of allergic disease. Adv Immunol 2004;82:105-53.
57. Jutel M, Pichler WJ, Skrbic D, Urwyler A, Dahinden C, Müller UR. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-γ secretion in specific allergen-stimulated T-cell cultures. J Immunol 1995;154:4187-94.
58. Ebner C, Siemann U, Bohle B, Wilheim M, Wiedermann U, Schenk S, et al. Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen. Clin Exp Allergy 1997;27:1007-15.
59. Akdis CA, Blesken T, Akdis M, Wüthrich B, Blaser K. Role of Interleukin 10 in specific immunotherapy. J Clin Invest 1998;102:98-106.
60. Van Ree R, Van Leeuwen WA, Dieges PH, Van Wijk RG, De Jong N, Brewczyski PZ, et al. Measurement of IgE antibodies against purified grass pollen allergens (Lol p 1, 2, 3 and 5) during immunotherapy. Clin Exp Allergy 1997;27:68-74.
61. Bousquet J, Lockey R, Malling HJ and the WHO panel members. Allergen immunotherapy: therapeutic vaccines for allergic diseases: A WHO position paper. J Allergy Clin Immunol 1998;102:558-62.
62. Valenta R. The future of antigen-specific immunotherapy of allergy. Nat Rev Immunol 2002;2:446-53.
63. Valenta R, Kraft D. Recombinant allergen molecules: tools to study effector cell activation. Immunol Rev 2001;179:119-27.
64. Vrtala S, Hirtenlehner K, Vangelista L, Pastore A, Eichler HG, Sperr WR, et al. Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitopecontaining fragments: candidates for a novel form of specific immunotherapy. J Clin Invest 1997;99:1673-81.
65. Ball T, Fuchs T, Sperr WR, Valent P, Vangelista L, Kraft D, et al. B cell epitopes of the major timothy grass pollen allergen, phl p 1, revealed by gene fragmentation as candidates for immunotherapy. FASEB J 1999;13:1277-90.
66. Valenta R, Vrtala S, Focke-Tejkl M, Bugajska-Schretter A, Ball T, Twardosz A, et al. Genetically engineered and synthetic allergen derivatives: candidates for vaccination against type I allergy. Biol Chem 1999;380:815-24.
67. Bhaila PL, Swoboda I, Singh MB. Reduction in allergenicity of grass pollen by genetic engineering. Int Arch Allergy Immunol 2001;124:51-4.
68. Vrtala S, Hirtenlehner K, Vangelista L, Pastore A, Eichler HG, Sperr WR, et al. Division of the major birch pollen allergen, Bet v 1, into two non-anaphylactic fragments. Int Arch Allergy Immunol 1997;113:246-8.
69. Lowenstein H, Spacholt SH, Klysner SS, Ipsen H, Larsen JN. The significance of isoallergenic variations in present and future specific immunotherapy. Int Arch Allergy Immunol 1995;107:285-9.
70. Breiteneder H, Ferreira F, Hoffmann-Sommergruber K, Ebner C, Breitenbach M, Rumpold H, et al. Four recombinant isoforms of Cor a I, the major allergen of hazel pollen, show different IgE-binding properties. Eur J Biochem 1993;212:355-62.
71. Ferreira F, Hirtenlehner K, Jilek A, Godnik-Cvar J, Breiteneder H, Grimm R, et al. Dissection of immunoglobulin E and T lymphocyte reactivity of isoforms of the major birch pollen allergen Bet v 1: potential use of hypoallergenic isoforms for immunotherapy. J Exp Med 1996;183:599-609.
72. Vrtala S, Hirtenlehner K, Susani M, Akdis M, Kussebi F, Akdis CA, et al. Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen Bet v 1. FASEB J 2001;15:2045-7.
73. Linhart B, Jahn-Schmid B, Verdino P, Keller W, Ebner C, Kraft D, et al. Combination vaccines for the treatment of grass pollen allergy consisting of genetically engineered hybrid molecules with increased immunogenicity. FASEB J 2002;16:1301-3.
74. Niederberger V, Stubner P, Spitzauer S, Kraft D, Valenta R, Ehrenberger K, et al. Skin test results but not serology reflect immediate type respiratory sensitivity: a study performed with recombinant allergen molecules. J Invest Dermatol 2001;117:848-51.
75. Heiss S, Mahler V, Steiner R, Spitzauer S, Schweiger C, Kraft D, et al. Component-resolved diagnosis (CRD) of type I allergy with recombinant grass and tree pollen allergens by skin testing. J Invest Dermatol 1999;113:830-7.
76. Tresch S, Holzmann D, Baumann S, Blaser K, Wuthrich B, Crameri R, et al. In vitro and in vivo allergenicity of recombinant Bet v 1 compared to the reactivity of natural birch pollen extract. Clin Exp Allergy 2003;33:1153-8.
77. Arquint O, Helbling A, Crameri R, Ferreira F, Breitenbach M, Pichler WJ. Reduced in vivo allergenicity of Bet v 1d isoform, a natural component of birch pollen. J Allergy Clin Immunol 1999;104:1239-43.
78. van Hage-Hamsten M, Kronqvist M, Zetterström O, Johansson E, Niederberger V, Vrtala S, et al. Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1. Results obtained with a mix of two recombinant Bet v 1 fragments and rBet v 1 trimer in a Swedish population before the birch pollen season. J Allergy Clin Immunol 1999;104:969-77.
79. Pauli G, Purohit A, Oster JP, de Blay F, Vrtala S, Niederberger V, et al. Comparison of genetically engineered hypoallergenic rBet v 1 derivatives by skin prick and intradermal testing: results obtained in a French population. Clin Exp Allergy 2000;30:1076-84.
80. Nopp A, Halden G, Lundhal J, Johansson E, Vrtala S, Valenta R, et al. Comparison of inflammatory responses to genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1, induces less eosinophilic activity in skin chamber fluids collected from birch pollen allergic patients than rBet v 1 wild type. J Allergy Clin Immunol 2000;106:101-9.
81. Kauppinen J, Zeiler T, Rautiainen J, Rytkonen-Nissinen M, Taivainen A, Mantyjarvi R, et al. Mutant derivatives of the main respiratory allergen of cow are less allergenic than the intact molecule. Clin Exp Allergy 1999;29:989-96.
82. Kronqvist M, Johansson E, Whitley P, Olsson S, Gafvelin G, Scheynius A, et al. A hypoallergenic derivative of the major allergen of the dust mite Lepidoglyphus destructor, Lep d 2.6Cys, induces less IgE reactivity and cellular response in the skin than recombinant Lep d 2. Int Arch Allergy Immunol 2001;126:41-9.
83. Bonura A, Amoroso S, Locorotondo G, Di Felice G, Tinghino R, Geraci D, et al. Hypoallergenic variants of the Parietaria judaica major allergen Par j 1: a member of the non-specific lipid transfer protein plant family. Int Arch Allergy Immunol 2001;126:32-40.